CD36 tango in cancer: signaling pathways and functions.
Wang J, Li Y. · 2019
Read CD36 tango in cancer: signaling pathways and functions. by Wang J, Li Y. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6691380.txt.
Introduction
Wang and Li review CD36 signalling pathways and functions in cancer. Their overview appears in Theranostics. CD36 is a scavenger receptor on many cell types. It takes up lipids and recognises dying cells. Thrombospondin-1 and fatty acids are key ligands. In tumours the receptor plays opposing roles. On cancer cells it fuels metastasis. Enhanced lipid uptake and oxidation drive that effect. Therapy resistance follows the same route. On tiny vessel walls it blocks new vessel growth instead. Thrombospondin binding triggers cell death there.
Tumour-linked immune cells add another layer. CD36-driven reprogramming promotes immune tolerance. Expression rises as tumours progress to metastasis. Control networks governing the receptor are mapped. Clinical trials targeting CD36 are surveyed.
Catalog record
| CREATOR | Wang J, Li Y. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
CD36 tango in cancer: signaling pathways and functions By Jingchun Wang, Yongsheng Li Published in: Theranostics DOI: 10.7150/thno.36037 ABSTRACT Abstract CD36, a scavenger receptor expressed in multiple cell types, mediates lipid uptake, immunological recognition, inflammation, molecular adhesion, and apoptosis. CD36 is a transmembrane glycoprotein that contains several posttranslational modification sites and binds to diverse ligands, including apoptotic cells, thrombospondin-1 (TSP-1), and fatty acids (FAs). Beyond fueling tumor metastasis and therapy resistance by enhancing lipid uptake and FA oxidation, CD36 attenuates angiogenesis by binding to TSP-1 and thereby inducing apoptosis or blocking the vascular endothelial growth factor receptor 2 pathway in tumor microvascular endothelial cells. Moreover, CD36-driven lipid metabolic reprogramming and functions in tumor-associated immune cells lead to tumor immune tolerance and cancer development. Notable advances have been made in demonstrating the regulatory networks that govern distinct physiological properties of CD36, and this has identified targeting CD36 as a potential strategy for cancer treatment. Here, we provide an overview on the structure, regulation, ligands, functions, and clinical trials of CD36 in cancer. Keywords: CD36, cancer treatment, biomarker, lipid metabolism, tumor-associated immune cell INTRODUCTION Lipid metabolism is currently attracting increasing research attention because of its critical role in tumor initiation, development, and metastasis 1. Adipocytes supply adequate fatty acids (FAs) to meet the high energy requirement of tumor cells and fuel their development, and tumor cells also show increased propensity to migrate toward adipose tissues, where they can uptake sufficient lipids 2. CD36, a transmembrane glycoprotein (GP) that is also known as FA translocase (FAT), platelet GPIV, GP88, and scavenger receptor class B type 2 (SR-B2), is expressed on the cell surface in multiple cell types, including dendritic cells (DCs), microvascular endothelial cells (MVECs), retinal epithelial cells, monocytes, adipocytes, platelets, enterocytes, microglial cells, and podocytes 3. In tumor tissues, CD36 is expressed in tumor cells and in stromal and immune cells, but the expression level varies in distinct cell types and tumor stages. CD36 expression is invariably low in the in situ stage but increases during metastasis 4, and CD36 plays essential roles in lipid homeostasis, angiogenesis, immune response, adhesion, and metastasis in cancer 4, 5. Therefore, CD36 is now regarded as a potential biomarker and therapeutic target for cancer. CD36: DISCOVERY, STRUCTURE, AND DISTRIBUTION Discovery of CD36 In 1973, Kobylka and Carraway discovered a membrane protein in breast epithelial cells that could not be hydrolyzed in milk fat globules 6, and in 1978, the molecule was identified as platelet GPIV, a protein that mediates thrombospondin-1 (TSP-1) binding in platelets 7. Subsequently, Tandon found that GPIV featured an overlapping structure with leukocyte-differentiation antigen CD36, and other investigators later determined the effects of CD36 in platelet activation 8 and cell adhesion 9. In 1993, Abumrad and colleagues demonstrated the FAT activity of CD36, after which the protein in mice was cloned and identified as the mouse ortholog of human CD36, which indicated its role in FA uptake 10. CD36 is now widely recognized as a scavenger receptor that can absorb long-chain FAs (LCFAs) and oxidized low-density lipoprotein (ox-LDL) 11, 12. Structure of CD36 The human CD36 gene is located at chromosome 7q11.2 and is related to the GP gene family. The gene is ~46 kb long and includes 15 exons, and polymorphisms have been identified at >32 bases in the human gene 13. Human CD36 contains ~472 amino acids and its estimated molecular weight is 53 kDa 10; the protein harbors two transmembrane domains, a large extracellular region containing ligand-binding sites, and a single short cytoplasmic tail at each terminal (N and C) (Figure 1). The extracellular domain of CD36 forms two hydrophobic cavities that mediate the uptake of hydrophobic molecules such as FAs, phospholipids, and cholesterol 13. Moreover, in CD36, the CD36, LIMP-2, Emp sequence homologous (CLESH) domain residues are negatively charged and can interact with TSP-1 repeat domain 2 (TSR) to regulate tumor angiogenesis, platelet aggregation, and other reactions, and CD36 also harbors a lysine-cluster region that can bind to negatively charged ligands 14. Almost all end-stage oxidative products are negatively charged, including ox-LDL, apoptotic cells, and advanced oxidation protein products (AOPPs) 15, which might be present at adequate levels in areas that exhibit heightened metabolism, such as in tumor tissues. [Figure: Structure of CD36. (Above) CD36 harbors two transmembrane domains, a large extracellular region containing ligand-binding sites, and one short cytoplasmic tail at each terminal (N and C). The extracellular domain of CD36 forms two hydrophobic cavities that bind to ligands such as fatty acids and oxidized LDL (ox-LDL). Moreover, the CLESH domain (CD36, LIMP-2, Emp sequence homologous domain) residues are negatively charged and interact with TSP-1 repeat domain 2 (TSR). CD36 undergoes multiple posttranslational modifications, including palmitoylation, acetylation, glycosylation, phosphorylation, ubiquitylation, and disulfide bonding (at three sites), and these modifications control CD36 maturation and localization in cells. Conversely, ligands bind to CD36 in different regions, and the binding leads to the activation of various downstream pathways. (Below) CD36 primary structure showing the hydrophobic domain and binding sites of general ligands. The numbers in different colors denote amino acid sites that undergo posttranslational modification: red, palmitoylation; green, glycosylation; blue, phosphorylation; dark blue, ubiquitylation; purple, acetylation.] Besides the transmembrane form of CD36, a soluble form of the protein, sCD36, is also generated, and this form was shown to be composed of the exposed extracellular domain of transmembrane CD36 that is shed by plasma proteases or a specific subset of circulating microparticles 16. The mechanism underlying sCD36 generation warrants further investigation. CD36 distribution in cancer In tumor tissues, CD36 is expressed in tumor cells 4, MVECs 17, stromal cells 5, and immune cells 18, and the CD36 level varies in distinct cell types. In malignant epidermal tumor cells, such as in the cells of ovarian cancer 19, gastric cancer 20, glioblastoma (GBM) 21, and oral squamous cell carcinoma (OSCC) 4, CD36 expression is markedly upregulated, whereas in tumor microvessels, which support tumor development and metastasis, CD36 expression is generally downregulated. CD36 expression is also deficient in the tumor stroma. For example, CD36 expression level in breast cancer stroma is considerably lower than that in adjacent tissues. Furthermore, a strong risk factor associated with high prevalence of breast cancer is high mammographic density (MD), and high-MD (but cancer-free) tissues were also shown to express reduced levels of CD36 5. These lines of evidence suggest that CD36 deficiency is representative of the tumor stroma and high cancer risk: the lower the CD36 level in the stroma, the more aggressive the tumor. CD36 is widely recognized as a plasma membrane protein. On the cell membrane, CD36 and caveolin-1 can co-polymerize in plasma membrane domains called caveolae 22, which are specialized cell-membrane microdomains that are rich in cholesterol, sphingomyelin, signaling molecules, and receptor proteins and promote the integration of signaling cascades 23. CD36 can be transported to organelle and cell membranes by intracellular and extracellular vesicles and can regulate FA uptake and the balance of energy metabolism. CD36 transport to the cell membrane can be facilitated by several physiological stimuli, the most potent of which are insulin and muscle contraction. Muscle contraction induces CD36 localization in the cell membrane by activating adenosine 5ʹ-monophosphate-activated protein kinase (AMPK) 24, whereas insulin produces this effect by activating the phosphatidylinositol